India, June 25 -- Ionis Pharmaceutical Inc. (IONS), a commercial-stage biotechnology company, on Thursday announced entering a license agreement with Recordati (REC.MI), a pharmaceutical company, for the international commercialization rights of Zilganersen in treating Alexander disease.
According to the terms of the agreement, Ionis will retain all commercialization rights for Zilganersen within the U.S. The company will receive an upfront payment of $30 million, in addition to various milestone payments and up to 20% in royalties on potential net sales of the drug.
Recordati assumes responsibility for all regulatory filing and commercialization outside the U.S.
Alexander disease (AxD) is a rare, progressive, and ultimately fatal neurol...